Manipulation of autoimmune diseases with T-suppressor cells: lessons from experimental SLE and EAE.
Shoenfeld
Y
Y
Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel.
Blank
M
M
Aharoni
R
R
Teitelbaum
D
D
Arnon
R
R
D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002478:Cells, Cultured; D003433:Crosses, Genetic; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D006825:Hybridomas / Q000276:immunology / Q000637:transplantation; D007108:Immune Tolerance; D007113:Immunity, Innate / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C / Q000276:immunology; D008810:Mice, Inbred C57BL / Q000276:immunology; D013491:Suppressor Factors, Immunologic / Q000172:deficiency / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation
D001323:Autoantibodies; D007376:Interleukin-2; D013491:Suppressor Factors, Immunologic; C013256:soluble immune response suppressor